Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine, Rochester, MN, highlights the absence of randomized control trials specifically focusing on preventative treatments for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). While immunotherapy has shown promise for acute treatment, comprehensive studies in preventative measures remain elusive. Dr Redenbaugh points to upcoming trials that aim to delve deeper into this area, particularly focusing on interleukin-6 inhibition. The outcomes of these studies are eagerly anticipated, and the results may pave the way for innovative therapeutic interventions for MOGAD. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.